申请人:Pfizer, Inc.
公开号:US06040309A1
公开(公告)日:2000-03-21
Compounds of formula I, ##STR1## wherein X represents O or S(O).sub.m ; R.sup.1 and R.sup.2 independently represent phenyl, naphthyl or heteroaryl; each of which is optionally fused and optionally substituted; Y represents a bond, O, (CH.sub.2).sub.n, O(CH.sub.2).sub.n, (CH.sub.2).sub.n O, or CH(C.sub.1-6 alkyl)O; R.sup.3 represents H or C.sub.1-6 alkyl; m represents 0, 1, or 2; and n represents 1, or 2; and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of restenosis, renal failure and pulmonary hypertension.
化合物的结构式I,其中X代表O或S(O).sub.m;R.sup.1和R.sup.2分别代表苯基、萘基或杂环烷基;每个都可以融合和可以取代;Y代表键合、O、(CH.sub.2).sub.n、O(CH.sub.2).sub.n、(CH.sub.2).sub.n O或CH(C.sub.1-6烷基)O;R.sup.3代表H或C.sub.1-6烷基;m代表0、1或2;n代表1或2;以及其药学上可接受的盐,在治疗中具有用途,特别是在治疗再狭窄、肾功能衰竭和肺动脉高压方面。